Daniel Falk

8PUBLICATIONS
14CO-AUTHORS
Biologically active moleculesClinical psychologyPredictive and prognostic markersHealth psychologyCounselling psychology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (8)

|Dec 03, 2024
Effects of a novel GABA-B positive allosteric modulator, ASP8062, on alcohol cue-elicited craving and naturalistic alcohol consumption in a multisite randomized, double-blind, placebo-controlled trial.

Joseph P Schacht, Lara A Ray, Robert Miranda

|May 05, 2020
Effects of Alcohol Cue Reactivity on Subsequent Treatment Outcomes Among Treatment-Seeking Individuals with Alcohol Use Disorder: A Multisite Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Varenicline.

Robert Miranda, Stephanie S O'Malley, Hayley Treloar Padovano

|Apr 06, 2019
Maintenance of World Health Organization Risk Drinking Level Reductions and Posttreatment Functioning Following a Large Alcohol Use Disorder Clinical Trial.

Katie Witkiewitz, Daniel E Falk, Raye Z Litten

|Nov 08, 2018
Gabapentin Enacarbil Extended-Release for Alcohol Use Disorder: A Randomized, Double-Blind, Placebo-Controlled, Multisite Trial Assessing Efficacy and Safety.

Daniel E Falk, Megan L Ryan, Joanne B Fertig

|Nov 06, 2018
Drinking Risk Level Reductions Associated with Improvements in Physical Health and Quality of Life Among Individuals with Alcohol Use Disorder.

Katie Witkiewitz, Henry R Kranzler, Kevin A Hallgren

|Sep 12, 2018
Reduction in Nonabstinent WHO Drinking Risk Levels and Change in Risk for Liver Disease and Positive AUDIT-C Scores: Prospective 3-Year Follow-Up Results in the U.S. General Population.

Justin Knox, Melanie Wall, Katie Witkiewitz

Pageof 2

Frequent Collaborators

4 joint publications

Katie Witkiewitz

4 joint publications

Karl Mann

4 joint publications

Raymond F Anton

2 joint publications

Lara Ray